Adelaide, Australia and Liege, Belgium - Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXTSTELLIS (14.2 mg of estetrol and 3 mg drospirenone tablets), a firstof-its kind oral contraceptive with a novel estrogen is now available in Australia.

NEXTSTELLIS was approved by the Therapeutic Goods Administration (TGA) in November 2021 and is the first and only contraceptive pill containing a new low impact1 estrogen, estetrol (E4), and a progestin, drospirenone. E4 is a natural estrogen produced by the human body during pregnancy and in NEXTSTELLIS, E4 is derived from a plant source. NEXTSTELLIS will compete in the Australian combined (estrogen plus progestin) oral contraceptive market which is valued at A$60 million2 . Combined oral contraceptives continue to be the most common method of contraception with nearly 1 million Australian women using them.

Mayne Pharma's CEO Mr Scott Richards said: 'We are delighted to introduce NEXTSTELLIS to the Australian market. NEXTSTELLIS offers an effective, safe, and well-tolerated contraceptive pill with predictable cycle control and has demonstrated low impact on certain parts of the body. The launch will be supported by an expanded national GP/specialist sales team that are now educating healthcare professionals on the unique characteristics of E4.'

Mithra's CEO Mr Leon Van Rompay said: 'NEXTSTELLIS unlocks a new era in contraception offering women and their healthcare providers a next generation birth control pill. Every woman's body responds differently to contraceptive hormones and having a new estrogen available - E4 - opens up the possibility that more women will be able to find a combination that suits them. Mithra is excited to see the commercialisation of NEXTSTELLIS on a third continent.'

Contact:

Mayne Pharma

Lisa Pendlebury

VP

Investor Relations & Communications

T: +61 419 548 434

E: lisa.pendlebury@maynepharma.com

Investor

Mithra Benoit Mathieu

T: +32 473 35 80 18

E: investorrelations@mithra.com

Press

Maud Vanderthommen

T: +32 473 58 61 04

E: press@mithra.com

(C) 2022 Electronic News Publishing, source ENP Newswire